- Tuesday, November 15, 2016
-
PROGRAM B : New developments in AAAs, EVAR, aortic branch lesions, outpatent issues, laparoscopic techniques, complex AAAs, New techniques and open or hybrid vascular surgery.
SESSION 9: NEW DEVELOPMENTS IN AAAs AND EVAR
6:45 – 6:50 Indications For Open AAA Repair In The Current Advanced Endovascular Era Dittmar Böckler, MD
6:51 – 6:56 All AAA Patients Who Need Invasive Treatment Should Be Treated By EVAR If They Have Suitable Anatomy: This Includes Young Patients: This Is Why Mark Conrad, MD, MMSc
6:57 – 7:02 Propensity Matched Comparison Of EVAR vs. Open Repair In A Large US Medicare Database Show EVAR Benefits Up To 7 Years Later: Nevertheless, Open Repair Is Indicated In Young AAA Patients: This Is Why Marc L. Schermerhorn, MD
7:03 – 7:08 Interesting Insights From The RCTs Comparing EVAR To Open Repair After 12-15 Years Of Follow-Up: EVAR Benefits Are Not Durable And Reinterventions Continue To Be Needed Jan D. Blankensteijn, MD
7:09 – 7:14 Long-Term Results Of EVAR With Standard AAA Endografts: How Do These Results Differ From Those In The EVAR RCTs And Why Timur P. Sarac, MD
7:15 – 7:20 Are Advantages Of Lower AAA Related Mortality From EVAR vs. Open Repair Sustained Better With New Generation Devices: A Critical Comparison Of EVAR 1 vs. The ENGAGE Registry Dittmar Böckler, MD
7:27 – 7:32 How To Enable EVAR To Be Done For AAAs With Neck Diameters >36 mm: A Combination Of An Endologix AFX Endograft And A Larger Diameter Valiant Tube Graft Makes It Feasible Jean-Paul de Vries, MD, PhD
7:33 – 7:38 Value Of Hypnosis For EVAR And Other Endovascular Procedures To Make Them Even Less Invasive: How To Do It Jean-Pierre Becquemin, MD
7:39 – 7:44 How Are Long-Term EVAR Outcomes Impacted By Extremely Angled Necks, Conical Necks, And Necks With Circumferential Thrombus: It Doesn’t Seem To Matter If . . . Hence J.M. Verhagen, MD, PhD
7:45 – 7:50 Current Optimal Management Of Inflammatory AAAs: When Endo, When Open Franco Grego, MD
7:51 – 7:56 Inflammatory AAAs: Open vs. Endo Treatment And Tips And Tricks For Safely Treating With Open Repair Kenneth J. Cherry, MD
7:57 – 8:02 EVAR Techniques For Inflammatory AAAs And Other Rare AAAs Including Behçet’s Disease: How Effective And Durable Are They Furuzan Numan, MDSESSION 10: NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC BRANCH LESIONS – ESPECIALLY OF THE AORTO-ILIAC SEGMENT
8:09 – 8:14 What Proportion Of Aorto-Iliac Lesions Require Open Treatment: Tips And Tricks For Treating Endo Ali Amin, MD, RVT
8:15 – 8:20 Endovascular Treatment Of Juxtarenal Aortic Occlusions: Technique Of Treatment And Renal And Visceral Protection: Midterm Results Sonia Ronchey, MD, PhDNicola Mangialardi, MD
8:21 – 8:26 3-Year Results With The CERAB Procedure For Stent-Graft Reconstruction Of The Occluded Aortic Bifurcation: Technical Precautions, Advantages And Limitations Michel M.P. Reijnen, MD, PhD Peter C.J. Goverde, MD
8:27 – 8:32 How Can Chimney Grafts Be Used Effectively With The CERAB Procedure: Techniques And Results Peter C.J. Goverde, MD Michel M.P. Reijnen, MD, PhD
8:33 – 8:38 Endologix AFX EVAR Endograft For The Treatment Of Complex Aorto-Iliac Occlusive Disease: When Is It Indicated, How To Perform And Early Results Thomas S. Maldonado, MD
8:39 – 8:44 Is There Still A Role For Open Aortofemoral Bypass For Aorto-Iliac Occlusive Disease: What Is It And Why Michael Belkin, MD
8:45 – 8:50 At What Size Do Hypogastric Artery Aneurysms Rupture: At What Size Is Repair Indicated: Textbook Indications For Repair Should Change Maarit Venermo, MD, PhD
8:51 – 8:56 What Should Be Done About Hypogastric Aneurysms Excluded Only Proximally By Overstenting: At What Size Should Something Else Be Done And What Is That Something Frans L. Moll, MD, PhD
8:57 – 9:02 Comparison Of Available Iliac Branched Devices (IBDs) For Iliac Aneurysms And Hypogastric Revascularization: Advantages And Limitations Of Each Timothy A. Resch, MD, PhDSESSION 11: VASCULAR LAPAROSCOPY, SOME ROBOTICS AND NEW HELPFUL TECHNIQUES AND COMPARISONS
9:25 – 9:30 With New Developments In Laparoscopic Robotic Aortic Surgery, It May Still Have A Real Role In Vascular Treatment: Unlike My Impression Last Year Willem Wisselink, MD
9:31 – 9:36 Advances In Laparoscopic Robotic Surgery Indicate It Has A Bright Future For Treating Aortic And Visceral Artery Disease: How The Gore Hybrid Graft Facilitates This Fabien Thaveau, MD, PhD
9:37 – 9:42 Laparoscopic Aorto-Bifemoral Bypass: Indications And Advantages In An Endovascular World Joseph S. Giglia, MD
9:43 – 9:48 Laparoscopic Aortic Surgery Has More Adverse Events Than Open Aortic Surgery: A Propensity Matched Comparison With Well-Trained Laparoscopic And Open Surgeons Jean-Baptiste Ricco, MD, PhD
9:49 – 9:54 Endovascular Retroperitoneoscopic Technique Offers New Possibilities For Laparoscopic Aorto-Bifemoral Bypass In Complex TASC D Aorto-Iliac Lesions Bernard J. Segers, MD
9:55 – 10:00 Comparison Of AAA Sac Shrinkage After Fenestrated EVAR (F/EVAR) And Standard EVAR: F/EVAR Wins Neal S. Cayne, MD
10:01 – 10:06 Comparison Of Open Surgery, Hybrid Techniques And Fenestrated Or Branched EVAR (F/BEVAR) For TAAAs Piergiorgio Cao, MD
10:07 – 10:12 False Lumen Obliteration In Chronic TBADs Using An Inverted (“Flipped”) Cook Converter And Occlusion Plug Niten Singh, MDSESSION 12: NEW DEVELOPMENTS WITH JUXTA AND PARARENAL AORTIC ANEURYSMS AND THORACOABDOMINAL ANEURYSMS (TAAAs)
10:20 – 10:25 Current Status Of The Only FDA Approved Fenestrated Graft (ZFEN From Cook) That Is Commercially Available In The US: How Is Its General Adoption Doing Andres Schanzer, MD
10:26 – 10:31 With ZFEN F/EVAR, A Large SMA Scallop Can Cause Problems: What Are They And What Is The Solution Carlos H. Timaran, MD
10:32 – 10:37 What Is A Hostile Infrarenal Neck And When Should F/EVAR Be Done Rather Than Standard EVAR Matthew J. Eagleton, MD
10:38 – 10:43 When Can Standard EVAR Be Safely And Durably Performed In Patients With Hostile Necks Hence J.M. Verhagen, MD, PhD
10:44 – 10:49 In Most AAA Patients With Hostile Necks F/EVAR Is The Best Treatment: What Are The Exceptions Marcelo Ferreira, MD
10:50 – 10:55 In Most Patients With Hostile Necks Chimney EVAR (Ch/EVAR) Is The Best Treatment: What Are The Exceptions Giovanni Torsello, MD Konstantinos P. Donas, MD Jason T. Lee, MD
10:56 – 11:01 When Does Hybrid Endovascular Repair With Renal And Visceral Debranching Have A Role In Treating TAAAs: Patient Selection And Technical Tips Martin R. Back, MD
11:08 – 11:13 Prevention Of Visceral And Renal Branch Artery Complications During F/BEVAR: Selection Of The Optimal Bridging Stent-Graft Darren B. Schneider, MD
11:14 – 11:19 F/EVAR Cuffs vs. Ch/EVAR For Failed Standard EVAR: Indications, Advantages And Limitations Of Each Bijan Modarai, PhD
11:20 – 11:25 F/EVAR For Failed Standard EVAR: When Is It Indicated And When Must Open Repair Be Done Cherrie Z. Abraham, MD
11:26 – 11:31 Midterm Results Of Chimney Grafts For Pararenal AAAs: How To Make Them Work Nicola Mangialardi, MD
11:32 – 11:37 Adjuncts To Improve Outcomes Of Treatment For Challenging (Juxta And Pararenal) AAAs: Parallel Grafts, Endoanchors, New Endografts, Better Imaging, Simulation: Are They All Essential Or Not Isabelle van Herzeele, MD, PhD
11:38 – 11:43 Open Repair vs. Branched EVAR (B/EVAR) For Type IV TAAAs: When To Do Each And How Iliac Anatomy Influences Choice: B/EVAR Results Andrea Stella, MD
11:44 – 11:49 The COLT Endograft System For Treatment Of TAAAs: A Novel Simplified Endograft System From Jotec: How It Works: What Makes It Different And Early Clinical Results Piotr Szopinski, MDSESSION 13: BUSINESS ISSUES, NEW CONCEPTS
1:00 – 1:05 Value, Limitations And Abuses Of Outpatient Angio Centers: How To Limit Abuses Stephen M. Bauer, MD
1:06 – 1:11 Massive Use Of Atherectomy In Outpatient Facilities Is Self-Serving And Does Not Help Patients Dipankar Mukherjee, MD
1:12 – 1:17 What Is The Best Arterial Closure Device For Use In An Outpatient Setting: Incidence And Reasons For Failure And Technical Tips Sam S. Ahn, MD, MBA
1:18 – 1:23 When Is Outpatient Treatment Justified For Peripheral Occlusive Lesions: Precautions And Techniques Enrico Ascher, MD
1:24 – 1:29 How To Create A Medical Company Start-Up And Keep It: Creating A Corporation, Getting Funding, Value Of A Business Plan And More Timothy K. Liem, MD, MBA
1:30 – 1:35 When Is Enough Enough With Endovascular Options: Why Open Surgery Will Never Die Krishna Jain, MD
1:36 – 1:41 Endojunk And Its Management: What To Do With Materials Left In Situ Unintentionally During EVAR And TEVAR Ramesh K. Tripathi, MD
1:42 – 1:47 The Piculet Recanalization Device For Crossing Difficult CTOs: How It Works And When Is It Indicated Yann Gouëffic, MD, PhD
1:48 – 1:53 Intraoperative Arterial Quantitative Flow Measurements With The Medistem Vascular Flow Device: How Does It Work And Can It Help With Intraoperative Decisions And Postoperative Assessment Tej M. Singh, MD, MBASESSION 14: MORE NEW TECHNIQUES, CONCEPTS AND UPDATES
2:00 – 2:05 Value Of Phoenix 2.2 mm Atherectomy System (From Volcano) In Treating Lower Extremity Occlusive Lesions: It Cuts, Captures And Clears In 1 Step: How Does It Work And Early Results Luis R. Leon, MD, RVT
2:06 – 2:11 Superior Mesenteric Artery (SMA) Reimplantation For The Nutcracker Syndrome With Duodenal Obstruction: A Better Treatment Than Gastrojejunostomy Kenneth J. Cherry, MD
2:12 – 2:17 How To Make Thrombolysis More Precise And Effective With Microbubbles And EKOS Catheters: Results In Humans From The MUST Trial Kak Khee Yeung, MD, PhD
2:18 – 2:23 Value Of Ultrasound In The Operating Room In Planning, Access, Control Of Angioplasty Above And Below The Knee (BTK) And Closure Of The Puncture Site Enrique Puras, MD
2:24 – 2:29 Pioneering Techniques For The Endovascular Treatment Of Critical Upper Extremity Ischemia With Gangrene Roberto Ferraresi, MD
2:30 – 2:35 Update On The Current Status Of Stem Cell And Bone Marrow Therapy For CLI And Gangrene With Unfixable Distal Arteries Richard J. Powell, MD
2:36 – 2:41 Two Techniques To Facilitate F/BEVAR: 1) The Up-And-Over Technique For Endoconduit Solutions With Bad Iliac Access Arteries And 2) Progressive Main Graft Deployment With Sequential Branch Catheterization And Stent-Grafting To Permit Staging And To Deal With Narrow Aortas Carlos H. Timaran, MD
2:42 – 2:47 Physiological And Biomechanical Information From 4D Dynamic Imaging Can Help Us Understand And Guide The Management Of Aortic Disease: New Developments Rachel E. Clough, MD, PhD
2:48 – 2:53 Radial Access For Most Non-Coronary Interventions: Equipment, Techniques, Advantages, Risks And Limitations Marcelo Guimaraes, MD
2:54 – 2:59 Value And Advantages Of The Chocolate Balloon PTA Catheter (TriReme/Cordis): Theory Of Its Pillows And Groove Technology And Clinical Results (The ENDURE Trial) Jihad A. Mustapha, MD Andrew Holden, MBChBSESSION 15: RENAL AND VISCERAL ARTERY ISSUES AND NEW DEVELOPMENTS
3:20 – 3:25 Pancreaticoduodenal And Gastroduodenal Aneurysms: Indications And Precautions For Treatment And Which Is Best – Open vs. Endo James C. Stanley, MD
3:26 – 3:31 Pancreaticoduodenal Aneurysms: Technical Tips And Tricks For Open Repair Ronald M. Fairman, MD
3:32 – 3:37 Visceral Artery Aneurysms: When And At What Size Are They Dangerous And How Should They Be Fixed Armando Mansilha, MD, PhD
3:38 – 3:43 With Visceral And Renal Artery Aneurysms An Endovascular First Strategy Is Best For All Intact And Ruptured Cases: Are There Exceptions Rabih A. Chaer, MD
3:44 – 3:49 Incidence Of Embolization In Association With F/BEVAR: Is Late Renal Salvage After Renal Artery Occlusion Possible And What Is The Mechanism James F. McKinsey, MD
3:50 – 3:55 DCBs (In.Pact Admiral) Are A Better Treatment For Renal In Stent Restenosis (ISR) And Fibromuscular Hyperplasia Fabrizio Fanelli, MD
3:56 – 4:01 Remedial Operations For Failed Endovascular Treatments On Pediatric Renal Arteries Jonathan L. Eliason, MD James C. Stanley, MD
4:02 – 4:07 What Is The Best Current Treatment For Mesenteric Ischemia; When Endo, When Open, When Hybrid: Based On Outcomes Timur P. Sarac, MD
4:08 – 4:13 Retrograde SMA Revascularization Via Celiac Artery And Collaterals When Antegrade Techniques Fail: Technical Tips Timothy A. Resch, MD, PhD Nuno Dias, MD
4:14 – 4:19 Variably Curved Conformable Sheaths (Oscor Twist) Make A Major Difference In Endovascular Procedures: Like SMA Stenting From A Femoral Approach And Fenestrated And Branched EVAR Joshua D. Adams, MD Claudio J. Schonholz, MD
4:20 – 4:25 The Renal Guard Device To Prevent Contrast Induced Renal Injury In High Risk Patients: How Does It Work And Is It Effective Horst Sievert, MDSESSION 16: TOPICS RELATED TO OPEN SURGERY AND AORTIC COARCTATIONS
4:32 – 4:37 Status Of Balloon Expandable Stents And Stent-Grafts (Atrium V12 LD) For Treatment Of Aortic Coarctation: Results Of The COAST I And II Trials Elchanan Bruckheimer, MBBS
4:38 – 4:43 Long-Term Outcome Of Celiac Trunk Release For Celiac Axis Compression Syndrome: When Does The Artery Have To Be Treated And Open Surgery Is Best Jan D. Blankensteijn, MD
4:44 – 4:49 Open Surgery Is The Best Treatment For Coral Reef Lesions Of The Aorta And Visceral And Iliac Arteries: How To Diagnose Them And Why Endo Treatments Are No Good Laurent Chiche, MD
4:50 – 4:55 Tips And Tricks For Open Repair Of TAAAs As Primary Procedures And After Failed Endo Procedures: Including Use Of Sutureless Hybrid Graft (Gore) For Renal Revascularization Roberto Chiesa, MD Yamume Tshomba, MD
4:56 – 5:01 Indications For Open TAAA Repair In The Endovascular Era Hazim J. Safi, MD Anthony L. Estrera, MD
5:02 – 5:07 Role Of Ascending Aorta To Supra-Aortic Trunk Bypasses In The Endovascular Era: Technical Precautions And Tips John E. Rectenwald, MD, MS
5:14 – 5:19 Treatment Of Post TEVAR Aorto-Esophageal Fistula: Only Radical Surgery Can Prevent Patient Mortality: Steps In The Operative Treatment Michael J. Jacobs, MD
5:20 – 5:25 Distal Aortic Failure After TEVAR: When Is Open Repair Best And Tips And Tricks To Do It James H. Black III, MD
5:26 – 5:31 What Is The Role Of Aorto-Bifemoral Bypass For Aorto-Iliac Occlusive Disease In The Current Endovascular Era Mr. Michael G. Wyatt, MD
5:32 – 5:37 Value Of Hybrid Techniques For Treating Difficult CLI Patients: Advantages And Techniques Carlo Setacci, MD
5:38 – 5:43 What Is The Role Of Open Surgical Distal Lower Extremity Bypass In The Current Endovascular Era R. Clement Darling III, MD
5:44 – 5:49 After Multiple Failed Endovascular Treatments, Open Bypasses Can Save Limbs Julien G. Sfeir, MD
- Wednesday, November 16, 2016
-
PROGRAM E : Medical and anti-athrogenic treatments, anti-hypertensive treatments; endoleak treatments: endoleak managements; issues and other interesting topics.
SESSION 31: MONITORING HEPARIN; SCREENING FOR AND ASSESSING ATHEROSCLEROTIC RISK; ANTI- ATHEROSCLEROSIS TREATMENT CHANGES IN LIGHT OF NEW TRIAL FINDINGS; UPDATE ON TIMING OF SURGERY IN PATIENTS WITH CORONARY STENTS
6:40 – 6:45 Incidence And Importance Of Heparin Resistance In Vascular Procedures And How Measurement Of ACT Can Offset This Problem: Value Of Medtronic Hemostasis Management System Arno M. Wiersema, MD, PhD Kak Khee Yeung, MD, PhD Jan D. Blankensteijn, MD
6:46 – 6:51 Pleiotropic Effect Of Statins: What Are They And How Should They Be Monitored Anthony J. Comerota, MD
6:52 – 6:57 The Value Of Ultrasound Screening Of Femoral And Carotid Arteries To Predict Atherosclerotic Risk And What To Do About It Andrew N. Nicolaides, MS
6:58 – 7:03 The VIVA RCT Is A Game Changer: It Shows That Population Based Screening For AAA, PAD And Hypertension Allows Intensive Medical Treatment With Statins And Anti-Hypertensives And That These Drugs Save Lives (7%) Jes S. Lindholt, MD
7:04 – 7:09 Current Role Of PCSK 9 Inhibitors In LDL-Cholesterol (LDL-C) Management: How Do They Work And When Should They Be Given (Alirocumab-Praluent From Sanofi & Regeneron And Evolocumab-Repatha From Amgen) Ron Waksman, MD
7:10 – 7:15 How To Manage Muscle Pain And Apparent Statin Intolerance In Patients On Statins: It Can Be Often Done Safely And Effectively Without Stopping Statins: What Does The GAUSS-3 Trial Tell Us About Controlling The Side Effects Of Statins Don Poldermans, MD
7:16 – 7:21 Why LDL-C (Or Non-HDL-C) Levels Are Important Guides To Treatment And Should Be Followed In Primary And Secondary Event Prevention For Vascular Patients At Risk: Coronary Lesions Regress When LDL-C Is <80 mm/dL Jeffrey S. Berger, MD, MS Caron B. Rockman, MD
7:22 – 7:27 Value Of Ezetimibe (Zetia) In Decreasing Death, Stroke And MI Rates When Added To Simvastatin: What Value Of LDL-C Should Our Patients Strive To Achieve: The IMPROVE-IT Trial: What Does The HOPE 3 Trial Tell Us About Crestor And Primary Prevention Ido Weinberg, MD, MSc
7:28 – 7:33 New Key Findings From The JUPITER Trial: Statins (Crestor) Have Variability In Their LDL-C Lowering Ability; The Degree Of Cardiovascular Risk Reduction Correlates With The Percent LDL-C Reduction: Therapeutic Implications Jeffrey S. Berger, MD, MS Jonathan Newman, MD
7:34 – 7:39 What Is New About Optimal Timing For Elective Vascular Surgery After Coronary Stenting For Angina; For MIs; With BMSs; With DESs: Things Have Changed: Risks Are Higher If The Stenting Was Done For An MI Caron B. Rockman, MD Jeffrey S. Berger, MD, MSSESSION 32: DRUG RESISTANT HYPERTENSION AND ITS CATHETER-BASED TREATMENTS; MEDICAL TREATMENTS; FRACTIONAL FLOW RESERVE; ASSESSMENT OF AAA RISK; UNUSUAL VASCULAR DISEASES
7:46 – 7:51 Why Pharmacological Treatments Are Insufficient To Control Hypertension In Some Patients And What Is The Outlook For Non-Pharmacologic Treatments Such As Renal Denervation And Baroreflex Stimulation (Neostim) And Modulation (Mobius) Melvin D. Lobo, MBChB, PhD
7:52 – 7:57 What Is New With Endovascular Treatments Of Drug Resistant Hypertension: New Better Devices Like The Peregrine And Paradise Systems For Renal Denervation: New Study Results: Future Predictions Horst Sievert, MD
7:58 – 8:03 Renal Artery Denervation For Hypertension: Why Hasn’t It Worked And Where Is It Going Krishna J. Rocha-Singh, MD
8:04 – 8:09 Update On The ROX Endovascular System For Creating An Iliac A-V Fistula To Treat Resistant Hypertension: How It Works, Results And Complications David H. Deaton, MD
8:10 – 8:15 Diagnostic Strategy For Children With Suspected Renin Mediated Hypertension Is Multimodal: Is Endovascular Treatment Ever Effective Kyung Cho, MD
8:16 – 8:21 What’s New In The Pharmacologic Prevention And Treatment In Patients With Arteriosclerotic Vascular Disease – Where Are We Currently With Statins, PCSK 9 Inhibitors And Platelet Inhibitors Iris Baumgartner, MD
8:22 – 8:27 Update On The Value Of Coronary CT And Fractional Flow Reserve (FFRct): Does It Eliminate Unnecessary Coronary Angiograms And Stents; Will The Technique Work In The Lower Extremity Christopher K. Zarins, MD
8:28 – 8:33 How Skin Biopsy Can Predict AAA Growth Rates And Rupture Kak Khee Yeung, MD, PhD
8:34 – 8:39 Systemic Inflammatory Disease: What Is It And How To Diagnose It: Does It Predict Increase Risk Of Post EVAR Complications, Type 2 Endoleak And Rupture Alan Dardik, MD, PhD
8:40 – 8:45 Segmental Arterial Mediolysis: What Is It; What Is Its Clinical Significance; How To Diagnose And Treat It Samuel R. Money, MD, MBASESSION 33: SIGNIFICANCE AND TREATMENT OF ENDOLEAKS AND AORTO-BRONCHIAL FISTULAS
8:54 – 8:59 Embolization For Type 1A Endoleaks After Nellix And Standard Endografts: How To Do It And When Does It Work And When Does It Not Robert A. Morgan, MD
9:00 – 9:05 How Does Onyx Work For Treating Type I Endoleaks: Limitations And Advantages Thomas Larzon, MD, PhD
9:06 – 9:11 Value Of Duplex Ultrasound In Treating Endoleaks In The Presence Of Coils And Onyx And With Nellix Grafts Dipankar Mukherjee, MD
9:12 – 9:17 Characterization System For Type 2 Endoleaks: What Is Its Clinical Significance Nicos Labropoulos, BSc (Med) PhD, DIC, RVT
9:18 – 9:23 The Natural History Of Type 2 Endoleaks That Develop After 1 Year Is Different: >70% Persist And Require Closer Surveillance And More Interventions Keith D. Calligaro, MD Matthew J. Dougherty, MD
9:24 – 9:29 Catheter-Based CT Guided Translumbar Endoleak Treatment: Technique And Advantages Stephan Haulon, MD
9:30 – 9:35 Accessory Renal Arteries – A Siginficant Source Of Bad Type 2 Endoleaks: How To Prevent, Diagnose And Treat Them Claudio J. Schonholz, MD Joshua D. Adams, MD
9:36 – 9:41 What Are The Causes Of Type 3 Endoleaks: Can Trauma Be One Of Them Carlo Setacci, MD
9:42 – 9:47 AAA Wall Angiogenesis, A Previously Unrecognized Cause Of Endoleaks After EVAR: How To Diagnose And Treat Them Eric Allaire, MD, PhD
9:48 – 9:53 Can Aorto-Bronchial Fistulas Be Managed Endovascularly: What Is The Hope Of Long-Term Survival Carlos E. Donayre, MDSESSION 34: IMPORTANT ISSUES FOR VASCULAR SURGEONS AND SPECIALISTS; REMEMBRANCES; ASSET PROTECTION; KEY MEDICAL, HISTORICAL AND ETHICAL TOPICS
10:16 – 10:21 Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly Jerry Goldstone, MD
10:22 - 10:27 Predictions For The Future In The Treatment Of Vascular Disease: Where Is Vascular Surgery Going Mark A. Adelman, MD
10:28 – 10:33 Negotiating With Large Health Care Systems: Tips And Tricks For Individual Vascular Surgeons: How Could A Union Or Society Help Timothy M. Sullivan, MD
10:34 – 10:39 Beyond Vascular Surgery For Vascular Surgeons: Working With Industry: What Is Good About It And What Is Bad David H. Deaton, MD
10:40 – 10:45 Why Vascular Surgeons Are An Essential Operating Room Resource For Other Surgeons: They Must Be Valued As Such, Protected And Compensated Gregory L. Moneta, MD
10:46 – 10:51 Is It A Wild West Bonanza Or A Feeding Frenzy: How To Stem The Surge In Unnecessary Lower Extremity Interventions That Cost So Much And Do Little To Benefit Patients Scott L. Stevens, MD
10:52 – 10:57 Key Points In Asset Protection, Tax Planning And Succession Planning For Vascular Surgeons/Specialists Hillel Presser, Esq., MBA
11:04 – 11:09 Optimal Treatment For Left Main Coronary Lesion Is Changing: Stenting With DESs Is Replacing Open Coronary Bypass: Based On The EXCEL Trial Gregg W. Stone, MD
11:10 – 11:15 COURAGE Trial Findings After 15 Years Follow-Up: It Still Shows No Advantage Over Medical Treatment In Some Coronary Disease Patients: Are Too Many Patients Getting Coronary Stents Roxana Mehran, MD
11:16 – 11:21 Role Of Stents In The Treatment Of Lower Extremity Occlusive Lesions: Value Of DESs And DCBs: Will Bare Metal Stent Usage Decrease Or Disappear John H. Rundback, MD
11:22 – 11:27 Current Status Of Cell And Gene Therapy For CLI Treatment: Do Either Have A Future Sigrid Nikol, MD
11:28 – 11:33 Long-Term Results Of Autologous Bone Marrow Cell Treatment For No Option CLI: Results Of A Double Blinded RCT Thomas F. O’Donnell, Jr., MD Mark D. Iafrati, MD
11:34 – 11:39 What Are “Octopus” Endografts: Why Are They The Future Of Branched Endografting For TAAAs And What Is Their Origin Karthikeshwar Kasirajan, MD
11:40 – 11:45 Ethical Conflicts In Providing Quality Care With All The Financial And RVU Pressures In The Current Health Care System: How To Resolve Them James W. Jones, MD, PhD, MHA
11:46 – 11:51 How To Involve Vascular Patients In Decision Making About Their Surgical And Interventional Treatments Dirk T. Ubbink, MD, PhDSESSION 35: THE CURRENT HEALTH CARE SYSTEM; REIMBURSEMENT; IMPACT OF OBAMACARE (ACA), ACOs, ETC. ON VASCULAR SURGEONS/SPECIALISTS AND OUR INDUSTRY PARTNERS
1:00 – 1:05 Effects Of The Massachusetts Universal Health Care Program On Vascular Surgery And Its Outcomes: Is It A Model For What Will Happen Under Obama Care Or The Affordable Care Act (ACA) Mohammad H. Eslami, MD, MPH
1:06 – 1:11 Obamacare 2016: Is It As Bad As Predicted Or Worse: Can It Be Fixed Clifford J. Buckley, MD
1:12 – 1:17 Is The ACA (Obamacare) Increasing Or Decreasing Access To Affordable Care Bruce A. Perler, MD, MBA
1:18 – 1:23 Impact Of The ACA On Vascular Surgery’s Value To The Health Care System: It’s Not Good Richard J. Powell, MD
1:24 – 1:29 Impact Of The Medical Device Tax On Medical Innovation And Education: Will It Be Repealed Or Just Delayed: Other Effects Of The ACA On The Medical Device Industry And Its Support Of Continuing Medical Education Allison H. Giles, RN, JD
1:30 – 1:35 Alternate Payment Models And ACOs (Accountable Care Organizations): How Are They Working, Will They Work And What Will Their Impact Be On Vascular Surgeons Robert M. Zwolak, MD, PhD
1:36 – 1:41 Impact Of The Medicare Access And CHIP Reauthorization Act Of 2015 (MACRA) On US Vascular Surgeons: Why It Is A Big Problem Timothy F. Kresowik, MD
1:42 – 1:47 What Is Happening With Reimbursement For Vascular Surgeons: What Does The Future Hold Sean P. Roddy, MD
1:48 – 1:53 How To Survive In A Hostile Health Care Environment: Systematizing Vascular Doctor/Hospital Alignment And Making The Hospital Vascular Services More Profitable Without Doing Unnecessary Procedures Barry T. Katzen, MD
1:54 – 1:59 Starting A Vascular Surgery Service In A Public Safety Net Hospital Can Be Profitable: Tips And Strategies For Success During Insurance And Health Care Reform Charles J. Fox, MDSESSION 36: GOVERNING BODIES (BOARDS/RRC); INDEPENDENCE; MOC; MENTORSHIP; COMPETENCE; TRAINING/SIMULATION
2:06 – 2:11 History Of The American Board of Vascular Surgery (ABVS) – Where Does Vascular Surgery Stand – What Is Missing James C. Stanley, MD
2:12 – 2:17 Advantages To A Division Of Vascular Surgery When It Is Part Of A Department Of General Surgery H. Leon Pachter, MD
2:18 – 2:23 Why Vascular Surgery Needs To Be A Totally Independent Specialty And How Can We Get There Timothy M. Sullivan, MD
2:24 – 2:29 MOC (Maintenance Of Certification): Is It Valuable, In Need Of Modification Or A Waste Of Time And Money: Does Vascular Surgery Need More Independence With Its Own Board And RRC John F. Eidt, MD
2:30 – 2:35 Who Should Be Doing The Complex Open Vascular Surgery (Pararenal AAAs, TAAAs, Mesenteric And Tibial Bypasses): Trainee Experience Is Limited: Do We Need Regional Centers And What Are The Downsides Ronald L. Dalman MD
2:36 – 2:41 Major Open Surgery Experience Differences Between 5+2 And 0+5 Vascular Trainees: Does It Matter Murray L. Shames, MD
2:48 – 2:53 Role And Progress Of Women In Vascular Surgery: Value Of Mentorship And How To Promote It Robyn A. Macsata, MD
2:54 – 2:59 Should All Surgeons Have To Work On Simulators – Like Pilots O. William Brown, MD, JD
3:00 – 3:05 How To Shift Learning Curves From Patients To Models (Simulators) And How To Assess Technical Skills With Models Hans-Henning Eckstein, MD, PhD
3:06 – 3:11 Proficiency Based Stepwise Endovascular Training Improves Performance In The Hybrid Suite: A RCT (The PROSPECT Trial) Proves It Isabelle van Herzeele, MD, PhD Heidi Maertens, PhD
3:12 – 3:17 How To Determine Proficiency In EVAR And Radiation Safety: Does Simulator Training Help Lars B. Lönn, MD, PhD Torben V. Schroeder, MD, DMSc
3:18 – 3:23 How To Train Practicing Vascular Surgeons/Specialists For New Procedures; “Gloves On Training” Can Do It: What Are The Essential Elements Jon S. Matsumura, MDSESSION 37: NEW DEVELOPMENTS IN VASCULAR CARE, DRGs, TELEMEDICINE, REIMBURSEMENTS, REPORTING BAD PRACTICE AND THE FDA
3:40 – 3:45 How Does A Real-Time Dashboard Database Improve The Quality And Decrease The Cost Of Vascular Care Timothy M. Sullivan, MD
3:46 – 3:51 How Can Hospitalists Improve A Vascular Service By Decreasing Mortality, Length Of Stay And Readmissions Peter L. Faries, MD
3:52 – 3:57 Volume/Outcome Relationship With CEA And CAS: German Registry Data From 175,000 Patients Hans-Henning Eckstein, MD, PhD
3:58 – 4:03 Hospital Volume Matters Most In Improving Outcome Of EVAR: Both Surgeon And Hospital Volume Matter For Open AAA Repair Marc L. Schermerhorn, MD
4:04 – 4:09 How To Incorporate Virtual Visits Into A Vascular Practice: The Technology Is Here: What Is The Technology And How To Use It John (Jeb) W. Hallett, MD
4:10 – 4:15 Role Of Telemedicine In A Vascular Practice: How To Be Reimbursed For It Clifford M. Sales, MD, MBA
4:16 – 4:21 Benefit Of New AAA/EVAR DRGs On Hospital Economics: They Are A Game Changer And How They Can Benefit Vascular Surgeons W. Charles Sternbergh III, MD
4:22 – 4:27 We Have A Duty To Report Unethical Procedures Or Malpractice To Hospital Administrators, State Misconduct Boards And Patients Seeking A Second Opinion: Why It Does Not Happen And What To Do If Such Reporting Does No Good Because Of Administrator Inaction O. William Brown, MD, JD
4:28 – 4:33 Ezetimbe (Zetia) Lowers LDL-C And Decreases Cardiovascular Death, MI And Stroke Over Statins Alone: When Should It Be Given And Why Didn’t The FDA Approve It Russell H. Samson, MD, RVT
4:34 – 4:39 Why Does The FDA Approve Lower Extremity Devices With Only 6-12 Months Follow-Up: Shouldn’t Longer Durability Be Required Dorothy B. Abel, BSBMESESSION 38: TRIALS/REGISTRIES; FLAWS IN REPORTING AND RCTs; PUBLICATION QUALITY; SVS STANDARDS AND GUIDELINES; FAIR DEVICE EVALUATION; VALUE OF VQIs
4:46 – 4:51 Registries vs. Trials: Pros And Cons Of Each: What Should Guide Clinical Practice Vicente Riambau, MD, PhD
4:52 – 4:57 Why Kaplan-Meier Analyses Are A Poor Way To Compare Devices And Treatments For PAD: How Should It Be Done Frank E.G. Vermassen, MD, PhD
4:58 – 5:03 Surgeon Outcome Reporting Can Be Inaccurate And Unreliable: What Is The Evidence Mr. Jonathan R. Boyle, MD
5:04 – 5:09 Critical Analysis Of Clinical Trials And Randomized Controlled Trials (RCTs): They Have Value But Many Pitfalls Anton N. Sidawy, MD, MPH
5:10 – 5:15 RCTs Are Often Poorly Generalizable: What Strategies Can Overcome This Flaw Charles C. Miller, PhD
5:16 – 5:21 With Published Articles In The Medical Literature Quality Should Trump Quantity: Does It And How Should Quality Be Evaluated Clifford J. Buckley, MD
5:28 – 5:33 Important Changes And Aspects Of The New SVS Reporting Standards Michael C. Stoner, MD
5:34 – 5:39 Highlights Of The New SVS Guidelines For Management Of The Diabetic Foot: Value Of Total Contact Cast For Diabetic Ulcers Anil P. Hingorani, MD
5:40 – 5:45 How To And How Not To Measure Quality: The Current System Has It Wrong Clifford M. Sales, MD, MBA
5:46 – 5:51 Two New Initiatives To Measure The Value Of Endovascular Devices Over Medical Treatment For Lower Extremity Occlusive Lesions: The Multidisciplinary RAPID Project And The VQI Registry Of Medical Treatment: How Do They Work Jack L. Cronenwett, MD
5:52 – 5:57 How Well Do VQI And Non-VQI Hospitals Perform In Quality Measures: Do Quality Measures Reflect Quality And Really Matter Philip P. Goodney, MD, MS
- Thursday, November 17, 2016
-
PROGRAM H : New devices for EVAR and juxtarenal AAA repair; TEVAR and TAAA repair; lower extremity treatment; updates on endoanchors; new devices for embolectomy and clot removal.
SESSION 55: NEW AND IMPROVED DEVICES FOR EVAR AND JUXTARENAL AAA REPAIR (4 ½ Minute Talks)
6:40 – 6:45 e CHAP Project (Characterization Of Human Aortic Anatomy Project): How Well Are Current EVAR Devices Able To Deal With Patient Diversity omas S. Maldonado, MD
6:50 – 6:55 EVAR Durability Up To 14 Years With e Cook Zenith Flex AAA Endogra Fabio Verzini, MD, PhD
6:55 – 7:00 e Cook Zenith Alpha AAA Endogra System: Advantages, Limitations And 1-Year Results Eric L.G. Verhoeven, MD, PhD
7:00 – 7:05 Advantages Of e New Medtronic Endurant EVO Device For EVAR: What Makes It Di erent And Early Global Results Gilbert R. Upchurch, MD
7:05 – 7:10 Clinical Results With e Cordis Incra Endogra Device For EVAR: Advantages And Limitations Germano Melissano, MD Robert Chiesa, MD
7:15 – 7:20 Long-Term (5-8 Years) Results With e Lombard Aor x Gra And 3-Year Results With e Improved Intelli ex Delivery System: How It Works Mahmoud B. Malas, MD, MHS Mark F. Fillinger, MD Andrew Holden, MBChB
7:20 – 7:25 Update On e ARCHYTAS Registry Results With e Lombard Aor x Endogra Used In Unfavorable Anatomy Vicente Riambau, MD, PhD
7:25 – 7:30 Update On e World Experience With e Ovation Endogra For EVAR: From TriVascular And Now Endologix Patrick Peeters, MD
7:30 – 7:35 Single Center Experience With e Ovation Endogra (TriVascular/Endologix) For EVAR: Advantages, Limitations And Use With Chimney Gra s Venkatesh G. Ramaiah, MD
7:35 – 7:40 Can Polymer Sealing Technology With e Ovation Endogra Treat Short Necked AAAs As Well As Fenestrated And Chimney Gra s: What Are e Limitations David J. Minion, MD
7:40 – 7:45 Aortic Neck Evolution A er EVAR With e Ovation Endogra : Does It Dilate As With Other Self-Expanding Endogra s Francesco Setacci, MD
7:50 – 7:55 Advantages And Limitations Of Lombard’s Altura Endogra Device To Simplify EVAR Procedures: A Multicenter Study David Murray, FRCS
7:55 – 8:00 Early Clinical Results With e Actively Conformable Gore Excluder (CEXC) EVAR Device For AAAs With Severely Angulated Necks: Concept And Advantages Marc R.H.M. van Sambeek, MD, PhD
8:00 – 8:05 US Experience With e Gore Iliac Branch Device (IBD) Excluder To Preserve Hypogastric Flow: Advantages, Limitations And Tips For Use Darren B. Schneider, MD
8:05 – 8:10 Results With e Cook Zenith IBD To Preserve Hypogastric Flow: e PRESERVE II Trial And A Ten-Year European Experience: Advantages And Limitations W. Anthony Lee, MD Fabio Verzini, MD, PhD
8:10 – 8:15 Parallel Gra s Work Very Well For Hypogastric Revascularization If Done Right: Tips For Doing And How ey Are More Versatile an IBDs Armando C. Lobato, MD, PhDSESSION 56: MORE NEW AND IMPROVED DEVICES FOR EVAR AND EVAS – SIMPLE AND COMPLEX; LIMITATIONS AND COMPLICATIONS (4 ½ Minute Talks)
8:20 – 8:25 Durability Is An Issue With e Newer Ultra Low Pro le Endogra s: How Can It Be Resolved Giovanni Pratesi, MD
8:25 – 8:30 Single Sided Access For EVAR With e Horizon Nexus Endogra : How Does It Work Mario L. Lachat, MD"
8:30 – 8:35 e Bolton Treovance Endogra For EVAR: Unique Features, Advantages, Limitations And Early US Results Daniel G. Clair, MD Matthew J. Eagleton, MD"
8:35 – 8:40 European Experience With e Bolton Treovance Endogra For EVAR: Midterm Results And Unique Advantages Including A Better Method For Revascularizing Hypogastric ArteriesAfshin Assadian, MD Burkhart Zipfel, MD, PhD Carlo Setacci, MD
8:40 – 8:45 Improvements In e Endologix AFX Device For EVAR: Mid- And Long-Term Complications And How ey Can Be Avoided And Treated Ignacio Escotto, MD
8:45 – 8:50 Failure Modes Of e AFX Endogra : How ey Can Be Detected And Treated Venkatesh G. Ramaiah, MD"
8:55 – 9:00 Long-Term Perspective On e Nellix Endogra From Endologix For Endovascular AAA Sealing (EVAS): From e GLOBAL FORWARD Registry: Will Nellix Be A Game Changer Andrew Holden, MBChB"
9:00 – 9:05 With Nellix Endogra s What Happens To AAA Sac Pressure With Endoleaks: How Is It Di erent From What Happens With Standard Endogra s Je rey P. Carpenter, MD"
9:05 – 9:10 Advantages And Disadvantages Of Nellix Endogra s For EVAS Based On Experience In 5000 Cases Dittmar Böckler, MD
9:10 – 9:15 How Does e Nellix Endogra Facilitate EVAR In Women And Asians Boonprasit Kritpracha, MD"
9:15 – 9:20 e Nellix Endogra s And EVAS: e Good, e Bad And e Ugly In A Busy Vascular Center Experience (200 Cases) Sebastian Zerwes, MD"
9:20 – 9:25 CT Imaging A er Nellix EVAS Procedures: How To Interpret em And Detect Endoleaks: What Happens To e Aortic Necks And How Does It Di er From Behavior With Standard Endogra EVARs Michel M.P. Reijnen, MD, PhD"
9:30 – 9:35 Late Failure Modes A er Nellix EVAS: Incidence, Mechanism And Treatment: How Do ey Di er From ose A er Standard EVAR Ian Lo us, MD Matt M. ompson, MD"
9:35 – 9:40 Infection A er Nellix AAA Repair: Incidence And How To Diagnose And Treat It Jan M.M. Heyligers, MD, PhD"
9:40 – 9:45 e Downsides And Limitations Of Nellix EVAS Repair Of AAAs Hence J.M. Verhagen, MD, PhD"
9:45 – 9:50 Limitations Of Nellix EVAS And What Precautions Must Be Taken When Using It Daniel G. Clair, MD"
9:50 – 9:55 What Happens When Nellix EVAR Fails: How To Diagnose It And What Are e Endovascular Bailouts Or Treatments Carlos E. Donayre, MD"SESSION 57: NEW AND IMPROVED DEVICES FOR THE ASCENDING AORTA, TEVAR, Ch/EVAR AND F/EVAR
10:18 – 10:23 Results Of Ascending Aortic Endogra ing With A Dedicated Cook Endogra : Indications, Limitations And Results Tilo Kölbel, MD, PhD Sebastian E. Debus, MD, PhD"
10:24 – 10:29 What Is e Safety Of Celiac Axis Coverage/Exclusion During Complex EVAR Or TEVAR: How To Martin R. Back, MD
10:30 – 10:35 3-Year US Results With e Bolton Relay Endogra For TEVAR: Unique Characteristics And Why ey Make A Di erence: Status With e FDA Mark A. Farber, MD
10:36 – 10:41 4- And 5-Year US And European Results With e Gore Conformable TAG Device For TEVAR: Concept, Advantages And Limitations Dittmar Böckler, MD William D. Jordan, Jr., MD
10:42 – 10:47 Multicenter Results And Advantages Of e Gore Conformable TAG Device For Treating TBADs (From e GREAT Registry) Santi Trimarchi, MD, PhD
10:48 – 10:53 A New “Gutterless” O - e-Shelf Device For Treating Pararenal And Paravisceral AAAs With Chimney EVAR: Concept And Results Timur P. Sarac, MD
10:54 – 10:59 World Results With e Vascutek Fenestrated Anaconda Endogra For Treatment Of Juxta And Pararenal AAAs: Advantages, Limitations And Results Donald B. Reid, MD
11:00 – 11:05 Advantages Of e Fenestrated Anaconda Gra In Treating Angulated No Neck AAAs: Why Type 1A Endoleaks O en Resolve With em Clark J. Zeebregts, MD, PhD Afshin Assadian, MD
11:06 – 11:11 Comparison Of Cook And Anaconda F/EVARs: Are ere Advantages Or Disadvantages To Each Gra System: From e GLOBALSTAR Registry Michael P. Jenkins, MBBS, BSc, MSSESSION 58: DEVICES AND APPROACHES TO TREAT THE THORACIC AORTA AND TAAAs
11:18 – 11:23 Transcarotid Access For TAVI And TEVAR: Indications, Precautions And Results Erno Remsey-Semmelweiss, MD Claude D. Vaislic, MD"
11:24 – 11:29 TEVAR With Proximal Scalloped O - e-Shelf Bolton Endogra s Perform Better an Le Subclavian (LSA) Branched Endogra s To Treat Most Lesions Near To Or Involving e LSA: Midterm ResultsJean-Marc Alsac, MD, PhD Michael P. Jenkins, MBBS, BSc, MS
11:30 – 11:35 Cook Zenith Alpha Low Pro le Endogra System For TEVAR: Advantages, Limitations And Clinical Results In Europe And e US Giovanni Torsello, MD W. Anthony Lee, MD"
11:36 – 11:41 Lower Pro le Deployment Systems And Small Diameter Endogra s Facilitate TEVAR Treatment Of Blunt Aortic Injuries In Young People: Is e Zenith Alpha System A Game Changer: Are ere Other Systems As Good Benjamin W. Starnes, MD"
11:42 – 11:47 e New Valiant EVO Device From Medtronic For TEVAR: What Makes It Better And Early Clinical Results Ali Azizzadeh, MD"SESSION 59: NEW DEVICES AND TECHNIQUES FOR TREATING LOWER EXTREMITY OCCLUSIVE DISEASE; PROSTHETIC GRAFTS AND HEPARIN BONDING
1:00 – 1:05 Impact Of Foot Infection On Leg Bypass Outcomes In CLI Patients: What Can Be Done To O set It Joseph L. Mills, MD"
1:06 – 1:11 Advantages And Early Clinical Experience With A Balloon at Does Not Straighten When It In ates: How Does It Work Timothy A.M. Chuter, DM"
1:12 – 1:17 Techniques For Performing Successful Bypasses To Heavily Calci ed (Pipe-Like) Tibial Arteries: Concept And Technical Tips For Rendering Bloodless, Incising And Suturing Enrico Ascher, MD Frank J. Veith, MD"
1:18 – 1:23 Advanced (Guide) Wiring Techniques For BTK And Foot Arteries For Interventional Treatments: What Di erence Do ey Make Hiroyoshi Yokoi, MD
1:24 – 1:29 Update On Spiral Laminar Flow Gra s: How Do ey Work And Do ey Prevent Intimal Hyperplasia And Enhance Patency Hosam F. El Sayed, MD
1:30 – 1:35 Heparin Bonded PTFE Gra s (Propaten From Gore) For BTK Bypasses In CLI: Advantages, Patency Results And Cost Issues Yann Gouë c, MD, PhD
1:36 – 1:41 DEBATE: Heparin Bonding Is Valuable In PTFE Fempop Bypass Gra s (Propaten): Long-Term Patency Results Show It Richard F. Neville, MD Russell H. Samson, MD, RVT"
1:42 – 1:47 DEBATE: Not So: Heparin Bonding Does Not Improve Results With PTFE Bypasses Jonathan D. Beard, ChM, Med"SESSION 60: NEW DEVELOPMENTS IN ARTERIAL GRAFTS; STENTS AND STENT-GRAFTS; CONCEPTS AND TECHNIQUES TO IMPROVE THEIR USE AND RESULTS
1:54 – 1:59 Tissue Engineered Blood Vessels For Arterial Bypass And Dialysis Access - ey Really Work: Midterm Results In Patients Je rey H. Lawson, MD, PhD
2:00 – 2:05 Present Status Of Bio-Resorbable DESs In e Heart And Peripheral Arteries: Future Potential And Is Increased Risk Of Stent rombosis A Problem Ron Waksman, MD
2:06 – 2:11 How Bio-Resorbable Stents Work And Why ey Should Improve Stent Outcomes: How Lessons Learned In e Coronary Arteries Can Be Applied To Other Arteries Richard J. Rapoza, PhD
2:12 – 2:17 Tack Optimized Balloon Angioplasty In e SFA And BTK Arteries: Concept, How It Works And 1-Year Results: e TOBA-BTK Trial Marianne Brodmann, MD
2:18 – 2:23 New Distal Filter Embolic Capture Device And Other Tips And Devices To Facilitate Lower Extremity And Pedal Interventions: 2.9 Fr Sheath And Compatible Balloon, O -Road Reentry Device, Etc. Andrej Schmidt, MD"
2:24 – 2:29 e New Cordis Smart Flex Stent: Advantages, Limitations And What Is Di erent: From e REALISTIC Trial Peter C.J. Goverde, MD Andrej Schmidt, MD"
2:30 – 2:35 e New Gore Hybrid (2-Component) Tigris Stent: Concept, Advantages And Clinical Results Maciej L. Dryjski, MD, PhD Konstantinos Katsanos, MSc, MD, PhD"
2:42 – 2:47 Value Of e Supera Stent In Non-Fempop Territories Rajiv Parakh, MBBS, MS
2:48 – 2:53 How To Optimally Deploy e Interwoven Supera Stent: Why It Matters: What Is e New Delivery System And Does It Help D. Christopher Metzger, MD
2:54 – 2:59 Supera vs. Standard Nitinol Stents For Chronic Total SFA Occlusions: Final Results Of e SUPERFAST Trial Konstantinos Katsanos, MSc, MD, PhD
3:00 – 3:05 Japanese Trial Of e Zilver PTX Stent In 974 Patients – Some With Long Di cult Lesions: 3-Year Results Con rm Its Value Kimihiro Komori, MD, PhD
3:06 – 3:11 Status Of DESs For Infrapopliteal Arteries: e Self- Expanding Paclitaxel Eluting Stentys Stent From Spectranetics Is Better an BMSs: >1-Year Results From e PES-BTK-70 Trial Show It Patrick Peeters, MD
3:12 – 3:17 New Viabahn Balloon Expandable Stent-Gra (From Gore): Its Value And 1-Year Results In Treating Iliac Artery Occlusive Disease: e VIABAHN BX Trial Andrew Holden, MBChBSESSION 61: ENDOLEAKS AND ENDOGRAFT MIGRATION: UPDATE ON ENDOANCHORS
3:36 – 3:41 Long-Term (>4 Years) Results Of Endoanchors In Minimizing EVAR Failures (Type 1A Endoleaks And Migration) In Hostile Aortic Necks: e ANCHOR Registry: When Don’t ey Work William D. Jordan, Jr., MD Jean-Paul de Vries, MD, PhD
3:42 – 3:47 In Patients With Hostile Neck Anatomy Endoanchors Prevent Endoleaks And Migration: A Propensity Matched Comparison Of EVAR In Hostile Neck Patients With And Without Endoanchors Bart E. Muhs, MD, PhD
3:48 – 3:53 Indications And Technical Tips For Placing Endoanchors With EVAR And Chimney EVAR Procedures: How Do We Know ey Work And Prevent Type 1A And Gutter Endoleaks Frank R. Arko, MD
3:54 – 3:59 Endoanchors Can Prevent And Treat Gutter Endoleaks With Parallel Gra s: Technical Tips And Midterm Results: When Will ey Not Work Zvonimir Krajcer, MD
4:00 – 4:05 Endoanchors (Heli-Fx, Aptus-Medtronic) During EVAR And Ch/EVAR Decrease Endoleaks And e Need For Reinterventions: When Don’t ey Work Manish Mehta, MD, MPH
4:06 – 4:11 Can AAA Neck Dilatation A er EVAR With Self- Expanding Endogra s Be Prevented By Endoanchors Apostolos K. Tassiopoulos, MD
4:12 – 4:17 Endoanchors In TEVARs And With Complex EVARs (F/EVAR And Ch/EVAR): When And How Should ey Be Used And What Is eir Value Jean M. Panneton, MD"
4:18 – 4:24 Endoanchors For TEVAR: When, Why And How Should ey Be Used Grayson H. Wheatley, MD"SESSION 62: NEW DEVICES FOR EMBOLECTOMY, CLOT REMOVAL AND EMBOLIZATION
4:32 – 4:37 Role Of Mechanical rombectomy And rombolysis In Acute Limb Ischemia: Technical Tips: When Is Open Operation Indicated Ali Amin, MD, RVT"
4:38 – 4:43 Treatment Of Embolic Complications Of Peripheral Interventions: It Is Not Just e Clot Which Must Be Removed: Value Of Suction Techniques And Devices Jos C. van den Berg, MD, PhD
4:44 – 4:49 Role Of Mechanical Debulking Devices To Optimize Endovascular Treatment: Value Of Rotarex And Aspirex Devices From Straub Medical: How ey Work And Results Michael K.W. Lichtenberg, MD"
4:50 – 4:55 Multicenter Retrospective Analysis Of Results Of Penumbra Indigo System For Mechanical Clot Aspiration From Arteries: How It Works, Indications, Vessel Sizes And Decreased Need For Lytics: e PRISM Registry James F. Benenati, MD Richard R. Saxon, MD
4:56 – 5:01 Why e Indigo Catheter Mechanical rombectomy System Is A Better Way To Remove Clot And Debris From Blood Vessels And Decrease e Need For Lytic Drugs Frank R. Arko, MD"
5:02 – 5:07 Value Of Indigo rombus Aspiration System In Acute Limb Ischemia And Visceral Artery romboses Or Emboli: Why It Is A Game Changer George L. Adams, MD
5:08 – 5:13 Endovascular Rescue Procedures For Acute Visceral Ischemia From rombo-Embolism; Tools, Devices, Tips And Tricks Andrej Schmidt, MD"
5:14 – 5:19 Use Of e Lantern Microcatheter And Ruby And POD Coils (Penumbra) For Arterial Embolization: What Are eir Advantages And Limitations TBD"
- Friday, November 18, 2016
-
PROGRAM K : Popliteal aneurysms and disease; management of infected arteries, prosthetic grafts and endografts; advances in imaging and hybrid suites; new developments in thoracic outlet syndromes, cardiac evaluation, vascular trauma, medical topics and treatments, CCSVI and radiation safety; recorded live cases from Münster & the Mayo clinic.
SESSION 79: NEW DEVELOPMENTS IN THE TREATMENT OF ANEURYSMS AND OTHER DISEASES INVOLVING THE POPLITEAL ARTERY
6:40 – 6:45 Why Do We Still Need Open Surgery For Some Popliteal Aneurysms: What Are The Indications – Relative And Absolute Jose Fernandes e Fernandes, MD, PhD
6:46 – 6:51 Comparison Of Open And Endo Popliteal Aneurysms Repair In The Same Patients Samy S. Nitecki, MD
6:52 – 6:57 DEBATE: Endovascular Repair Of Popliteal Aneurysms Is Less Risky Than Open Repair And Should Be The Procedure Of Choice: What Percent Of Patients Should Be Treated Endo Irwin V. Mohan, MBBS, MD
6:58 – 7:03 DEBATE: Not So: Open Repair Is Better For Most Popliteal Aneurysm Patients: Endo Repair Is Sometimes A Failed Experiment Martin Björck, MD, PhD
7:04 – 7:09 How Should Giant Popliteal Aneurysms Be Treated: Open vs. Endo And Tips And Tricks Jacques Busquet, MD
7:10 – 7:15 Duplex Guided Endovascular Repair Of Popliteal Aneurysms: Why It Is A Better Way Natalie A. Marks, MD, RPVI, RVT Enrico Ascher, MD Anil P. Hingorani, MD
7:16 – 7:21 New Developments In And Present Status Of Diagnosis And Treatment For Popliteal Entrapment Syndromes Niten Singh, MD
7:22 – 7:27 When Should Patients With Popliteal Arterial Compression Be Treated By PTA Plus Surgical Decompression: Long-Term (10-Year) Results Show It Is Sometimes The Better Treatment Beatrice R. Amann-Vesti, MD
7:28 – 7:33 Why Flexed Knee Angiography Should Always Be Performed To Control All Popliteal Interventions Or Procedures Roberto Ferraresi, MDSESSION 80: INFECTED ARTERIES AND ARTERIAL GRAFTS AND THEIR TREATMENT: INFECTED EVARs; MYCOTIC AAAs; INFECTED AORTIC/ARTERIAL PROSTHETIC GRAFTS; TREATMENT OF AORTO-ESOPHAGEAL FISTULA
7:40 – 7:45 DEBATE: Update On Treatment Of Infected Aortic Endografts: Open Surgical Graft Excision Is Always Indicated Kamphol Laohapensang, MD
7:46 – 7:51 DEBATE: Not So: Semi-Conservative Treatment Without Graft Excision And With Drainage And Antibiotic Irrigation Of AAA Sac Can Be Effective Treatment: Longer-Term Results Prove It Martin Malina, MD, PhD
7:52 – 7:57 Treatment Of Infected Abdominal Endografts: Radical vs. Conservative: Late Survival Results With Each Treatment – From A Multicenter Study Samuel R. Money, MD, MBA
7:58 – 8:03 Long-Term Outcome Of EVAR Treatment For Mycotic AAAs: What Risk Factors Impact On Late Survival I-Hui Wu, MD, PhD
8:04 – 8:09 When Aortic Infections And Mycotic AAAs Are Treated By EVAR, Early Success Does Not Equal Late Success: The Infection Returns: What To Do About It Ramesh K. Tripathi, MD
8:10 – 8:15 For Mycotic AAAs What Is The Value Of Endovascular Techniques And EVAR: When Are They Temporary Solutions And When Durable Treatment Thomas C. Bower, MD
8:16 – 8:21 Value Of Vein Graft Covered Stent For Treatment Of Mycotic AAAs: Technique And Results Klaus M. Overbeck, MD, MPhil
8:29 – 8:33 Intra-Abdominal Extra-Anatomic Reconstruction For Suprarenal Aortic And Graft Infection: Techniques And Results Manju Kalra, MBBS Thomas C. Bower, MD
8:34 – 8:39 Current Status Of Treatment For Aortic Graft Infection: When Should Cryopreserved Allografts Be Used And When Not: How Well Do They Work Long-Term Peter F. Lawrence, MD
8:40 – 8:45 New Developments In The Treatment Of Prosthetic Aortic Graft Infection Facilitate In Situ Repair: Negative Pressure Wound Therapy And Bovine Pericardium Vascular Grafts: Techniques And Results Max Zegelman, MD
8:46 – 8:51 Good Early Results Of Negative Pressure Wound Non-Excisional Treatment For Prosthetic Graft Infection Are Durable: It Is A Game Changer: Techniques And Long-Term Results Dieter O. Mayer, MD Barbara Hasse, MD Mario L. Lachat, MD Zoran Rancic, MD, PhD (Presenter)
8:52 – 8:57 Treatment Of Unilateral Limb Infection Of An Prosthetic Graft: Single Limb Excision Is Effective In ~50% Of Cases: When Should It Be Attempted: Diagnosis And Techniques Gregory L. Moneta, MD
8:58 – 9:03 How Best To Treat Infectious Complications Of Open And Endo Thoracic Aortic Repairs Germano Melissano, MD Roberto Chiesa, MD
9:04 – 9:09 Treatment Of Post-TEVAR Aorto-Esophageal Fistula: Only Radical Surgery Can Be Effective: Techniques And Sequence Of Treatment Michael J. Jacobs, MDSESSION 81: ADVANCES IN IMAGING, GUIDANCE AND HYBRID SUITES/ORS
9:24 – 9:29 What Vascular Surgeons Need To Know About Peripheral CT Angiography (CTA) And MR Angiography (MRA) To Make Them Most Valuable For Vascular Decision Making Michael H. Wholey, MD, MBA
9:30 – 9:35 3D Live Interactive Holography For Vascular: Advantages And Limitations Elchanan Bruckheimer, MBBS
9:36 – 9:41 Principles Of Fusion Techniques And Dyna-CT: Advantages And Limitations During EVAR And TEVAR Dittmar Böckler, MD
9:42 – 9:47 DEBATE: Hybrid Rooms With Fixed Fluoroscopy Units, Fusion And Dyna-CT Are Essential For Complex EVAR Procedures (F/BEVAR) Stephan Haulon, MD
9:48 – 9:53 DEBATE: Not So: Results With Complex EVARs (F/BEVAR) Performed With C-Arm Mobile Imaging Fluoroscopy Units Are As Good As Those Done With Fixed Equipment In A Hybrid Suite Geert Willem H. Schurink, MD, PhD
9:54 – 9:59 Advantages Of The Ziehm Vision RFD Hybrid Mobile Motorized C-Arm And Stille ImagiQ2 Floating Table: How Do They Compare With Fixed Hybrid Equipment For Complex Aortic Procedures Peter C.J. Goverde, MD
10:00 – 10:05 3D Fusion Is Possible With Any Digital C-Arm Mobile Fluoroscope Using The Cydar Software System: How It Works And Can Simplify And Improve Fusion Techniques Tom Carrell, MD, MChir Cynthia K. Shortell, MD
10:12 – 10:17 New Developments In Imaging That Are On The Horizon And That Will Change Our Management Of Most Complex Vascular Interventional Treatments Lieven F. Maene, MD
10:18 – 10:23 The Future Of Vascular Imaging And Guidance: Where Are They Going Alan B. Lumsden, MD
10:24 – 10:29 DEBATE: Ultrasound Imaging And Guidance Are The Best Method To Control Retrograde Distal Access Procedures And Crossing CTOs: Tips And Tricks Jihad A. Mustapha, MD
10:30 – 10:35 DEBATE: Not So: Fluoroscopy And Angiography Are The Best Way To Control Distal Puncture Procedures And Lesion Crossing: Technical Tips And Tricks Andrej Schmidt, MD
10:36 – 10:41 Advanced Imaging Tools (The Vessel Assist System From GE) Can Improve 3D Imaging And Fusion And Facilitate Lower Extremity And CAS Procedures Koen Deloose, MD
10:42 – 10:47 Why IVUS Use Should Become Standard Of Care In An Endovascular Practice: In What Procedures Is It A Must Donald B. Reid, MD
10:48 – 10:53 Update On Strategies To Reduce Contrast Induced Nephropathy: What Works And What Doesn’t Peter Henke, MDSESSION 82: NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs) AND CARDIAC EVALUATION
11:00 – 11:05 New Objective Outcomes Reporting For Neurogenic TOS Karl A. Illig, MD
11:06 – 11:11 Neurogenic TOS In Competitive Athletes: Is It Real: How Is It Best Diagnosed And Managed Michael J. Singh, MD
11:12 – 11:17 Diagnosis And Optimal Treatment For Neurogenic TOS: The Supraclavicular Approach For First Rib Resection Is Best: How To Do It Well Robert W. Thompson, MD
11:18 – 11:23 What Comprises TOS Specific Physical Therapy And How Often Is It Effective In Neurogenic TOS Jason T. Lee, MD
11:24 – 11:29 Robot Assisted Thoroscopic Minimally Invasive Treatment Of TOS Including First Rib Resection: How Is It Done (Video), Advantages And Limitations Hans M.E. Coveliers, MD, PhD, MBA
11:30 – 11:35 Optimal Way To Diagnose And Treat Venous TOS With Axillary-Subclavian Vein Thrombosis: Both The Supraclavicular And Infraclavicular Approaches Are Needed For Vein Exposure And Reconstruction Robert W. Thompson, MD
11:36 – 11:41 Tips And Tricks For Transaxillary First Rib Resection For Venous TOS: The Subclavian Vein Seldom If Ever Needs To Be Surgically Reconstructed Benjamin M. Jackson, MD
11:42 – 11:47 Infraclavicular Approaches To Venous TOS: Technique, Advantages And Limitation: What Can Be Done If The Subclavian Vein Needs To Be Reconstructed Or Cleaned Out Joseph J. Ricotta II, MD, MS
11:48 – 11:53 Are Cardiology Evaluations Of Any Value Before Vascular Operations: What Is Of Value: Current State Of The Art Peter Henke, MDSESSION 83: NEW OR UPDATED CONCEPTS AND TREATMENTS FOR VASCULAR TRAUMA AND TAKAYASU’S DISEASE; MEDICAL TOPICS AND TREATMENTS
1:00 – 1:05 How To Reduce Door-To-Reperfusion Time With Severe Arterial Trauma Markus K. Furrer, MD
1:06 – 1:11 New Developments In Endovascular Treatment And Balloon Occlusion For Major Arterial Trauma: What Is REBOA And Does Partial Aortic Balloon Occlusion Have Value Tal M. Hörer, MD, PhD
1:12 – 1:17 Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA) For Trauma Or Ruptured AAA: Is There A Role For IVUS Guidance To Facilitate Placement By Non-Interventionalists Donald L. Jacobs, MD
1:18 – 1:23 Update On An Improved Classification System, Devices And Techniques For Blunt Thoracic Aortic Injury (BTAI) Ali Azizzadeh, MD Benjamin W. Starnes, MD
1:24 – 1:29 Indications For Early Non-Operative Treatment With BTAI: It Is Safe And Lowers Mortality In Selected Patients: Indications For Early TEVAR Robert S. Crawford, MD Donald G. Harris, MD
1:30 – 1:35 Endovascular Treatment Of Traumatic Aortic Rupture In Children: What Devices Can Be Used For TEVAR Gabriel Szendro, MD
1:36 – 1:41 Tips And Tricks For Recognizing And Treating Acute Popliteal Artery Injuries (Lacerations And Occlusions) After Orthopedic Knee Surgery: They Are Often Missed Sohail Khan, MD
1:42 – 1:47 Bypasses vs. Endovascular Treatments For Symptomatic Takayasu’s Arteritis: Pros And Cons Of Each Byung-Boong Lee, MD
1:48 – 1:53 Current Management Strategies For Ehlers Danlos Syndrome And Role Of Endografts In The Treatment Of Its Arterial Lesions James H. Black III, MD
1:54 – 1:59 Preop Non-Invasive Fractional Flow Reserve (FFR) Evaluation Of Coronary Lesion Can Improve Care And Decrease Costs In Vascular Patients: Technique And Results Tej M. Singh, MD, MBASESSION 84: NEW DEVELOPMENTS AND UPDATES REGARDING CCSVI IN MULTIPLE SCLEROSIS; USE OF DRUGS IN VASCULAR DISEASE PATIENTS AND WAYS TO PREDICT RISKS OF ADVERSE EVENTS
2:08 – 2:13 Multicenter Blinded RCT To Determine Safety And Effectiveness (Quality Of Life) Of Venous PTA For Multiple Sclerosis (The BRAVE DREAMS Trial): Design And Progress: Will It Settle The Controversy Paolo Zamboni, MD
2:14 – 2:19 How Can Statins And Other Medical Treatment Decrease The Amputation And Major Adverse Limb Event Rates After Revascularizations For CLI: What Are The Optimal Drugs And Dosages Aravinda Najundappa, MD
2:20 – 2:25 Optimal Use Of ACE Inhibitors, Cilostazol, And Statins In Patients Undergoing Open And Endovascular Procedures Anthony J. Comerota, MD
2:26 – 2:31 Update On When And How Should Beta Blockers Be Used In Low Risk And High Risk Vascular Patients Generally And When They Undergo Operations And Interventions: Dosage Is Key Caron B. Rockman, MD Jeffrey S. Berger, MD, MS
2:32 – 2:37 Improving Non-Coronary Stent Outcomes By Pharmacological Manipulations – 2C19 And Plavix: How Do They Do It Karthikeshwar Kasirajan, MD
2:38 – 2:43 What Is New In Antiplatelet Treatment Of Vascular: Which Drugs In Which Situation: New Drugs And What Does The EUCLID Trial Tell Us Jeffrey S. Berger, MD, MS Caron B. Rockman, MD
2:50 – 2:55 Benefits Of Perioperative Statins In Improving Outcomes And Decreasing Adverse Events After AAA And Carotid Procedures – Endo And Open: Optimal Timing, Drug And Dosage Bruce A. Perler, MD, MBA
2:56 – 3:01 Update On The Medical (Drug) Treatment Of AAA Disease: What Does Metformin Do: Does Any Drug Slow AAA Growth Ronald L. Dalman, MD
3:02 – 3:07 Should Bivalirudin Replace Heparin In Non-Cardiac Interventions: Advantages And How To Use It George H. Meier III, MD
3:08 – 3:13 Biomarkers Can Predict Long-Term (~10 Years) Adverse Cardiovascular Events In Vascular Patients: Which Ones And How Can They Be Used Beatrice R. Amann-Vesti, MD
3:14 – 3:19 How To Identify Patients At Risk Of Cardiovascular Adverse Events After EVAR Janet T. Powell, MD, PhDSESSION 85: NEW CONCEPTS AND TECHNIQUES TO DECREASE RADIATION EXPOSURE FOR ENDOVASCULAR SURGEONS/SPECIALISTS AND PATIENTS
3:36 – 3:41 Crucial Elements In Radiation Safety For Non-Radiology Interventionists: Advice From A Radiologist Jos C. van den Berg, MD, PhD
3:42 – 3:47 Comparison Of Radiation Dosage And Safety Between Mobile C-Arm Fluoroscopes And Fixed Hybrid Units Mark G. Davies, MD
3:48 – 3:53 What Part Of Interventional Physicians Are At Risk From Radiation And Is Protective Gear Really Protective: Light Weight Lead Aprons Are A Hoax Lindsay Machan, MD
3:54 – 3:59 How To Minimize Radiation Exposure During Complex Endovascular AAA Repairs: Tips And Tricks Neal S. Cayne, MD
4:00 – 4:05 New Processing Software And Other Techniques For Reducing Radiation Exposure During Complex Interventional Procedures Carlos H. Timaran, MD
4:06 – 4:11 How OCT (Optical Coherence Tomography) Imaging Can Control Crossing Of CTOs And Decrease Radiation Exposure: So Too Can Expanded Use Of Duplex And IVUS Todd R. Vogel, MD, MPH
4:12 – 4:17 Worrisome Biologic And Dosimetric Effects Of Operator Radiation Exposure During Complex Interventional Procedures: How Can They Be Measured And Decreased Bijan Modarai, MD, PhD
4:18 – 4:23 Malignancies Occurring During CT Follow-Up Of EVAR: It Is A Real Risk And What To Do About It Ramesh K. Tripathi, MDSESSION 86: RECORDED LIVE CASES OF COMPLEX AORTIC ANEURYSM TREATMENT WITH ENDOVASCULAR TECHNIQUES
4:32 – 4:52 Complex Cases From Münster Giovanni Torsello, MD
4:52 – 5:02 Questions And Discussion
5:03 – 5:23 Complex Cases From The Mayo Clinic – Including Use Of A 3D Model With Pump Perfusion (Sande Stabile) For Planning And Simulation Gustavo S. Oderich, MD
0Join the discussion
Grand Ballroom West - Discussion
